Introduction
Hlx is partnering with a clinical-stage biotechnology company developing innovative therapies for rare renal diseases. With a lead programme in Phase II, the company is entering a critical stage of development and value creation.
We are seeking a hands-on Chief Medical Officer to work closely with the CEO as a true strategic partner. This role combines leadership and execution, with a strong emphasis on external engagement across investors, Key Opinion Leaders, and partners. The successful candidate will play a central role in shaping both the clinical strategy and the broader company narrative.
Responsibilities
- Lead the clinical development strategy and execution for the company’s Phase II programme and pipeline
- Provide hands-on oversight of trial design, execution, and data interpretation in a lean operating model
- Act as a key partner to the CEO on company strategy, prioritisation, and growth initiatives
- Play a central role in investor engagement, including fundraising, diligence, and presenting to investors and the Board
- Build and maintain strong relationships with global KOLs, investigators, and patient advocacy groups
- Represent the company at scientific congresses and industry events
- Lead regulatory interactions (FDA, EMA) and overall development pathway
- Integrate translational insights, including biomarkers and patient stratification strategies
- Support the build-out of the clinical and medical function as the company scales
Qualifications
- MD or MD/PhD; nephrology expertise strongly preferred - Ideally nephrologist or, cardio/metabolic focused
- Proven track record leading clinical development programmes through Phase II
- Demonstrated experience working closely with investors and KOLs in an externally facing capacity
- Prior experience in a small or mid-sized biotech environment preferred
- Strong strategic and operational capabilities; able to operate in a hands-on, resource-conscious setting
- Excellent communication skills with the ability to translate complex science for diverse audiences
- Credible external presence with regulators, investigators, and the investment community
Next Steps
For a confidential discussion or to express interest, please get in touch directly. We are actively engaging with a select group of candidates and welcome early conversations.